IRIS
MUSTO, Pellegrino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.188
AS - Asia 7.505
EU - Europa 6.052
SA - Sud America 3.278
Continente sconosciuto - Info sul continente non disponibili 1.044
AF - Africa 444
OC - Oceania 9
Totale 30.520
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.779
IT - Italia 2.812
SG - Singapore 2.694
BR - Brasile 2.594
HK - Hong Kong 1.308
CN - Cina 1.237
VN - Vietnam 839
RU - Federazione Russa 720
SE - Svezia 556
FR - Francia 554
DE - Germania 465
GB - Regno Unito 333
BD - Bangladesh 315
AR - Argentina 251
IN - India 236
FI - Finlandia 188
CA - Canada 167
MX - Messico 117
ID - Indonesia 114
IQ - Iraq 109
EC - Ecuador 100
ZA - Sudafrica 98
TR - Turchia 96
CO - Colombia 95
PK - Pakistan 84
CI - Costa d'Avorio 78
VE - Venezuela 71
SA - Arabia Saudita 61
PL - Polonia 59
MA - Marocco 58
UZ - Uzbekistan 58
PY - Paraguay 52
NL - Olanda 49
AT - Austria 48
JP - Giappone 47
UA - Ucraina 47
CL - Cile 46
TN - Tunisia 46
PH - Filippine 44
ES - Italia 40
EG - Egitto 37
PE - Perù 36
IE - Irlanda 35
MY - Malesia 32
KE - Kenya 29
JM - Giamaica 27
JO - Giordania 27
AZ - Azerbaigian 25
CR - Costa Rica 22
CZ - Repubblica Ceca 22
DZ - Algeria 21
KZ - Kazakistan 19
NP - Nepal 19
ET - Etiopia 18
IL - Israele 16
BE - Belgio 15
BO - Bolivia 15
HN - Honduras 15
LT - Lituania 14
OM - Oman 14
AE - Emirati Arabi Uniti 13
CH - Svizzera 13
SN - Senegal 13
TH - Thailandia 12
UY - Uruguay 12
DO - Repubblica Dominicana 11
TT - Trinidad e Tobago 11
KR - Corea 10
LB - Libano 10
AL - Albania 9
PA - Panama 9
RS - Serbia 9
GR - Grecia 8
GT - Guatemala 8
NI - Nicaragua 8
PS - Palestinian Territory 8
SY - Repubblica araba siriana 8
AU - Australia 7
BG - Bulgaria 7
BH - Bahrain 7
KG - Kirghizistan 7
XK - ???statistics.table.value.countryCode.XK??? 7
AO - Angola 6
BY - Bielorussia 6
EE - Estonia 6
GE - Georgia 6
TW - Taiwan 6
HR - Croazia 5
HU - Ungheria 5
LV - Lettonia 5
AM - Armenia 4
BA - Bosnia-Erzegovina 4
BB - Barbados 4
GY - Guiana 4
MU - Mauritius 4
NG - Nigeria 4
PT - Portogallo 4
BN - Brunei Darussalam 3
CW - ???statistics.table.value.countryCode.CW??? 3
KH - Cambogia 3
Totale 29.412
Salva come PNG Salva come JPEG
Città #
Singapore 1.513
Ashburn 1.375
Hong Kong 1.275
Milan 1.102
Fairfield 1.073
San Jose 1.014
New York 564
Council Bluffs 513
Nyköping 453
Chandler 395
Woodbridge 395
Houston 370
Rome 351
Lawrence 346
Seattle 342
Lauterbourg 339
Cambridge 337
Beijing 325
Ho Chi Minh City 307
Wilmington 297
Roxbury 284
Des Moines 240
Ann Arbor 218
Los Angeles 190
São Paulo 188
Santa Clara 179
Dallas 167
Hanoi 167
Helsinki 145
San Diego 128
Falkenstein 114
Paris 114
Bari 110
Columbus 98
Boardman 97
London 90
Munich 87
Chicago 83
Figino 83
Abidjan 78
Princeton 78
Turin 71
Buffalo 67
Frankfurt am Main 62
Rio de Janeiro 62
Nuremberg 57
Jakarta 54
Tashkent 54
Brooklyn 52
Phoenix 52
Atlanta 49
Belo Horizonte 48
Brasília 48
Jacksonville 48
Matera 48
Johannesburg 47
Porto Alegre 47
Potenza 47
Warsaw 47
Moscow 46
Inglewood 43
Campinas 41
Curitiba 41
Guayaquil 40
Mexico City 40
Baghdad 39
Da Nang 39
Tokyo 38
Denver 36
Dhaka 36
Chennai 35
Naples 35
Orem 35
San Francisco 35
Dublin 34
Haiphong 34
Montreal 34
Shanghai 34
Toronto 31
Guangzhou 29
Medellín 29
Salvador 29
Nanjing 28
Quito 28
Jeddah 27
Ribeirão Preto 27
Amman 26
Buenos Aires 26
Salt Lake City 25
Nairobi 24
Florence 23
Guarulhos 22
Karachi 22
Lahore 22
Lima 22
The Dalles 22
Turku 22
Casablanca 21
Hounslow 21
Vienna 21
Totale 17.846
Salva come PNG Salva come JPEG
Nome #
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 209
Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA 204
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets 199
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 194
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 193
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 183
Cardiovascular events and intensity of treatment in polycythemia vera. 182
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 175
Amyloid in bone marrow smears of patients affected by multiple myeloma 164
Differences among young adults, adults, and elderly chronic myeloid leukemia patients. 157
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma 156
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response 150
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 148
After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia 148
Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link? 140
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 140
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 140
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 137
RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia 133
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 132
Global methylation patterns in primary plasma cell leukemia 130
Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells 129
Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs 129
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 128
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 127
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 127
FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. 126
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 126
Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma 125
Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia 125
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 123
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project 120
Epitranscriptomics in normal and malignant hematopoiesis 118
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma 117
The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells 116
Analysis of amount, size, protein phenotype and molecular content of circulating extracellular vesicles identifies new biomarkers in multiple myeloma 113
Case report: biallelic DNMT3A mutations in acute myeloid leukemia 112
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 112
What Is New in the Treatment of Smoldering Multiple Myeloma? 112
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 112
Exploring the Potential of Eltrombopag: Room for More? 111
Single-Cell Sequencing: Ariadne's Thread in the Maze of Acute Myeloid Leukemia 109
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity 109
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study 108
90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma 106
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) 105
Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study 105
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 104
Can the new and old drugs exert an immunomodulatory effect in acute myeloid leukemia? 102
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 102
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis 102
Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick 102
Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia 101
null 101
IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater? 100
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 100
Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma 99
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 99
JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? 99
Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why? 98
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial 98
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 98
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial 98
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 98
Optical Genome Mapping as a Tool to Unveil New Molecular Findings in Hematological Patients with Complex Chromosomal Rearrangements 97
TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition? 97
Hypereosinophilia with a pinch of salt and pepper 97
Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia 96
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival 96
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: A pooled analysis of two studies 96
Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients 96
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 95
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 95
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 94
Immunomodulatory drugs in acute myeloid leukemia treatment 94
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event 93
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 93
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 93
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach. 92
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 92
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 91
Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients 91
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 90
Clonal hematopoiesis in clinical practice: walking a tightrope 90
Gastric normal adjacent mucosa versus healthy and cancer tissues: Distinctive transcriptomic profiles and biological features 90
The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation 90
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma 89
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. 89
The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy 88
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 88
New treatment strategies for elderly myeloma patients 88
Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia 87
Advanced mast cell disease: an Italian Hematological Multicenter experience 86
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches 86
The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms 85
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases 85
null 85
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant 85
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia 85
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice 85
Totale 11.434
Salva come PNG Salva come JPEG
Categoria #
all - tutte 185.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 185.075
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.679 0 0 17 35 20 291 110 85 244 196 287 394
2022/20231.717 404 234 142 66 102 192 111 142 232 18 46 28
2023/20241.195 97 139 78 56 102 459 57 28 2 14 22 141
2024/20255.890 158 25 392 102 152 615 540 421 338 382 878 1.887
2025/202614.626 1.792 630 1.063 1.860 1.268 614 1.171 532 1.556 1.582 511 2.047
2026/20271.923 649 842 432 0 0 0 0 0 0 0 0 0
Totale 30.520